Tags

Type your tag names separated by a space and hit enter

Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model.
Biochem Biophys Res Commun 2019; 518(2):306-310BB

Abstract

The aim of this study was to determine the efficacy of oral recombinant methioninase (o-rMETase) on a colon cancer primary tumor using a patient-derived orthotopic xenograft (PDOX) nude mouse model. Forty colon cancer primary tumor PDOX mouse models were divided into 4 groups of 10 mice each (total 40 mice) by measuring the tumor size. The groups were as follows: untreated control; 5-fluorouracil (5-FU) (50 mg/kg, once a week for two weeks, N = 10 mice) and oxaliplatinum (OXA) (6 mg/kg, once a week for two weeks, N = 10 mice); o-rMETase (100 units/day, oral 14 consecutive days, N = 10 mice); combination of 5-FU + OXA and o-rMETase (N = 10 mice). All treatments inhibited tumor growth compared to the untreated control. The combination of 5-FU + OXA and o-rMETase was significantly more efficacious than other treatments. The present study demonstrates the efficacy of o-rMETase combination therapy on a PDOX colon cancer primary tumor, suggesting potential clinical development of o-rMETase in recalcitrant cancer.

Authors+Show Affiliations

AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.AntiCancer Inc, San Diego, CA, USA.AntiCancer Inc, San Diego, CA, USA.AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA.Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov.Department of Surgery, University of California, San Diego, CA, USA.Department of Surgery, University of California, San Diego, CA, USA.AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31421825

Citation

Park, Jun Ho, et al. "Efficacy of Oral Recombinant Methioninase Combined With Oxaliplatinum and 5-fluorouracil On Primary Colon Cancer in a Patient-derived Orthotopic Xenograft Mouse Model." Biochemical and Biophysical Research Communications, vol. 518, no. 2, 2019, pp. 306-310.
Park JH, Zhao M, Han Q, et al. Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun. 2019;518(2):306-310.
Park, J. H., Zhao, M., Han, Q., Sun, Y., Higuchi, T., Sugisawa, N., ... Hoffman, R. M. (2019). Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. Biochemical and Biophysical Research Communications, 518(2), pp. 306-310. doi:10.1016/j.bbrc.2019.08.051.
Park JH, et al. Efficacy of Oral Recombinant Methioninase Combined With Oxaliplatinum and 5-fluorouracil On Primary Colon Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. Biochem Biophys Res Commun. 2019 Oct 15;518(2):306-310. PubMed PMID: 31421825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model. AU - Park,Jun Ho, AU - Zhao,Ming, AU - Han,Qinghong, AU - Sun,Yu, AU - Higuchi,Takashi, AU - Sugisawa,Norihiko, AU - Yamamoto,Jun, AU - Singh,Shree Ram, AU - Clary,Bryan, AU - Bouvet,Michael, AU - Hoffman,Robert M, Y1 - 2019/08/14/ PY - 2019/07/30/received PY - 2019/08/08/accepted PY - 2019/8/20/pubmed PY - 2019/8/20/medline PY - 2019/8/19/entrez KW - Colon cancer KW - Methioninase KW - Patient-derived orthotopic xenograft KW - Primary tumor KW - Red fluorescent protein SP - 306 EP - 310 JF - Biochemical and biophysical research communications JO - Biochem. Biophys. Res. Commun. VL - 518 IS - 2 N2 - The aim of this study was to determine the efficacy of oral recombinant methioninase (o-rMETase) on a colon cancer primary tumor using a patient-derived orthotopic xenograft (PDOX) nude mouse model. Forty colon cancer primary tumor PDOX mouse models were divided into 4 groups of 10 mice each (total 40 mice) by measuring the tumor size. The groups were as follows: untreated control; 5-fluorouracil (5-FU) (50 mg/kg, once a week for two weeks, N = 10 mice) and oxaliplatinum (OXA) (6 mg/kg, once a week for two weeks, N = 10 mice); o-rMETase (100 units/day, oral 14 consecutive days, N = 10 mice); combination of 5-FU + OXA and o-rMETase (N = 10 mice). All treatments inhibited tumor growth compared to the untreated control. The combination of 5-FU + OXA and o-rMETase was significantly more efficacious than other treatments. The present study demonstrates the efficacy of o-rMETase combination therapy on a PDOX colon cancer primary tumor, suggesting potential clinical development of o-rMETase in recalcitrant cancer. SN - 1090-2104 UR - https://www.unboundmedicine.com/medline/citation/31421825/Efficacy_of_oral_recombinant_methioninase_combined_with_oxaliplatinum_and_5-fluorouracil_on_primary_colon_cancer_in_a_patient-derived_orthotopic_xenograft_mouse_model L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(19)31568-2 DB - PRIME DP - Unbound Medicine ER -